* Straumann Monotype FullCeram implants serve as a suitable alternative for implant therapy especially in the aesthetic zone * The survival rate of Straumann Ceramic implants should be at least 85% (max 6 implant losses out of 40 patients) after the first year
This is a prospective, open label, single arm, multicenter study. The total study duration for each patient was prolonged to 10 years follow-up. It is acceptable to have the visit performed up to 6 month after the aspired date. The primary study parameter will be analyzed as soon as every patient passed visit 6 (annual follow-up visit, 12 month +/- 4 weeks). Implants will be placed transmucosally and will be protected by a thermoplastic splint for healing. A provisional prosthesis will be placed (out of occlusion) 12-14 weeks post implant placement. The final crown will be done between study week 24 and 28. Implant survival, implant success, bone loss, periodontal parameters and adverse events will be assessed in the follow-up visits. In total 10 visits are scheduled in this study. The investigational device: Straumann FullCeram Implant is a monotype ZrO2 implant with a diameter of 4.1 mm, available in lengths of 8, 10, 12 and 14 mm and abutment heights of 4.0 or 5.5 mm. This is a CE marked product. Three centres in Germany are participating. The study and any amendments will be performed as far as possible according to ISO 14155 (Second Edition, 2011-02-01) and conform to the Declaration of Helsinki (last revised Seoul 2008) and local legal and regulatory requirements.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
OTHER
Masking
NONE
Enrollment
44
FullCeram implantation
Medizinische Hochschule Hannover Klinik und Poliklinik fuer Mund-, Kiefer- und Gesichtschirurgie
Hanover, Germany
Oralchirurgie T1
Munich, Germany
Katharinenhospital
Stuttgart, Germany
The Implant Survival
A surviving implant is an integrated implant in the patient's jaw bone at the time of assessment.
Time frame: Measured at 12 months +/- 4 weeks after implant placement
The Implant Success
According to Buser et al 1992 an implant will be deemed a success if all of the following success criteria apply. * Absence of persisting subjective discomfort such as pain, foreign body perception and or dysaesthesia (painful sensation) * Absence of a recurrent peri-implant infection with suppuration (where an infection is termed recurrent if it is observed at two or more follow-up visits after treatment with systemic antibiotics) * Absence of implant mobility on manual palpation * Absence of any continuous peri-implant radiolucency
Time frame: Measured at Week 26, Month 12, Month 24 and Month 36
Mean Bone Level Changes (Distal and Mesial)
A radiographic stent was produced to have a standard measurement. The distal and mesial bone levels were combined into a single value by averaging the two values. Negative bone level changes representing bone loss between baseline and follow-up visits, vice versa positive changes representing bone gain.
Time frame: Measured at Week 26, Month 12, Month 24 and Month 36
The Implant Survival
A surviving implant is an integrated implant in the patient's jaw bone at the time of assessment.
Time frame: Measured at Week 26, Month 24 and Month 36
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.